We are an immuno-oncology company advancing a pipeline of next generation, transformative cancer treatments.
Location: United States, Massachusetts, Watertown
Employees: 11-50
Total raised: $128M
Founded date: 2017
Investors 8
Funding Rounds 2
| Date | Series | Amount | Investors |
| 07.01.2021 | Series B | $72M | - |
| 20.11.2019 | Series A | $56M | - |
Mentions in press and media 11
| Date | Title | Description |
| 07.03.2024 | Werewolf Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update | - |
| 06.03.2024 | Werewolf Therapeutics to Present at the 2024 Leerink Partners Global Biopharma Conference | - |
| 05.03.2024 | Werewolf Therapeutics Announces Upcoming Presentations at AACR Annual Meeting 2024 | - |
| 07.04.2022 | NASDAQ Roundtable: $JAZZ signs Agreement with $HOWL Today: Is $AVCO a Leader in Therapeutics next? Avalon (NASDAQ: AVCO) | $AVCO Therapeutics to fight Cancer AVCO Rings NASDAQ Bell Werewolf Therapeutics logo Werewolf Therapeutics $AVCO NASDAQ $AVCO a Leading global developer of cell-based Technologies & Therapeutics be next? Avalon Globocare Corp. (NASDAQ: ... |
| 10.06.2021 | WEREWOLF THERAPEUTICS, INC. Werewolf Therapeutics : Reports First Quarter 2021 Financial Results - Recently completed upsized initial public offering raising $120.0 million in gross proceeds (Form 8-... | Werewolf Therapeutics Reports First Quarter 2021 Financial Results - Recently completed upsized initial public offering raising $120.0 million in gross proceeds - Cambridge, Mass., June 10, 2021 - Werewolf Therapeutics, Inc. (the 'Company' ... |
| 07.01.2021 | Werewolf Therapeutics Completes $72 Million Series B Financing | Werewolf Therapeutics, Inc., an oncology biotherapeutics company advancing a pipeline of next-generation, transformative cancer treatments, today announced the completion of its $72 million Series B financing. The proceeds from the Series B... |
| 07.01.2021 | Werewolf banks $72M to shepherd shape-shifting cancer meds into phase 1 | A year after coming out of the shadows, Werewolf Therapeutics is kicking it up a notch. With $72 million in new financing, the company will push two shape-shifting cytokine drugs into the clinic and ramp up its discovery and preclinical wor... |
| 07.01.2021 | Werewolf banks $72M to shepherd shape-shifting cancer meds into phase 1 | A year after coming out of the shadows, Werewolf Therapeutics is kicking it up a notch. With $72 million in new financing, the company will push two shape-shifting cytokine drugs into the clinic and ramp up its discovery and preclinical wor... |
| 20.11.2019 | Werewolf Therapeutics Launches with $56M Series A Financing | Werewolf Therapeutics, an oncology biotherapeutics company advancing a pipeline of next generation, transformative cancer treatments, today announced the completion of its $56 million Series A financing. The company is developing novel immu... |
| 20.11.2019 | Werewolf Therapeutics Growls with $56M Series A | CAMBRIDGE, MA, Oncology biotherapeutics company announced the completion of its $56 million Series A financing. >> Click here for more funding data on Werewolf Therapeutics >> To export Werewolf Therapeutics funding data to ... |
Show more